WO2013055994A1 - Antimicrobial glass-ceramics - Google Patents
Antimicrobial glass-ceramics Download PDFInfo
- Publication number
- WO2013055994A1 WO2013055994A1 PCT/US2012/059872 US2012059872W WO2013055994A1 WO 2013055994 A1 WO2013055994 A1 WO 2013055994A1 US 2012059872 W US2012059872 W US 2012059872W WO 2013055994 A1 WO2013055994 A1 WO 2013055994A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glass
- antimicrobial
- range
- component
- article
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
- A01N59/20—Copper
Definitions
- This disclosure is directed to antimicrobial glass-ceramics, and in particular antimicrobial glass-ceramics containing silver, copper or a combination of silver and copper.
- the present disclosure is directed to the formation of an antimicrobial glass-ceramic ("GC") having an amorphous phase and a crystalline phase and an antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper.
- GC antimicrobial glass-ceramic
- Another aspect of the disclosure is a method of making a antimicrobial article having at least one selected antimicrobial agent therein, the method comprising the steps of providing a glass-ceramic substrate without an antimicrobial agent thereon, the glass-ceramic substrate having a crystalline component and an amorphous component; and subjecting said glass-ceramic substrate to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt to thereby form a antimicrobial glass-ceramic article, wherein the antimicrobial agent(s) is selected from the group consisting of copper, silver and a mixture of copper and silver.
- the silver and copper, or mixture thereof can be zero valent existing in the GC as Ag° or Cu°, which is the metallic form; can be ionic and exist in the GC as Ag +1 , Cu +1 or Cu +2 ; or can be in the GC as a mixture of the zero valent and ionic forms of one or both agents, for example, Ag° and Cu +1 and/or Cu +2 , Ag +1 and Cu°, and other combination of the zero valent and ionic species.
- the antimicrobial agent can be incorporated into the GC by either (1) ion-exchange of a preformed GC using an ion-exchange bath containing one or both of the foregoing antimicrobial agents, or (2) by including one or both of the foregoing antimicrobial agents into batched materials used to prepare a glass that is then cerammed to form a GC.
- the antimicrobial agent will be present in the GC in ionic form, as the oxide, since nitrates of the antimicrobial agent can be used for the ion-exchange and because the nitrate species on the GC are easily decomposed during the ion-exchange process.
- the antimicrobial agent is also deemed present as the oxide due to the conditions of melting, forming, nucleating and ceramming the glass, all of which can be carried out in air. In either case the resulting antimicrobial agent containing GC can be used as-is or can be subjected to a reduction step.
- Figure 1 is an electron microprobe (EMP) analysis of a spodumene-type glass-ceramic after ion-exchange using a 5wt% AgN0 3 /95wt% NaN0 3 bath at 420°C for 20 minutes.
- EMP electron microprobe
- Figure 2A is an EMP analysis after ion-exchange using a 5wt%
- Figure 2B is an Ag map of the glass-ceramic of Figure 2A.
- Figure 3 is a photograph of a spodumene GC (a) after ion-exchange at 420°C for 20 minutes using 5wt% Ag in a NaN0 3 bath (top, GC is white) and (b) after reduction at 420°C for 5 hours in H 2 at 1 atmosphere pressure (bottom, GC is grey).
- Figure 4A and 4B are SEM micrographs of the surface ( Figure 4A) and edge
- Figures 5A-5C are SEM micrographs of the spodumene GC of Figures 4A/4B after reduction at 450°C for 5 hours in 1 atmosphere H 2 .
- Figure 6 is the EMP analysis of a spodumene GC containing 1 mole% CuO as-made after heat treatment at 1100°C.
- the term "antimicrobial,” means an agent(s) or material, or a surface containing the agent(s) or material that will kill or inhibit the growth of microbes from at least two of families consisting of bacteria, viruses and fungi.
- the term as used herein does not mean it will kill or inhibit the growth of all species microbes within such families, but that it will kill or inhibit the growth or one or more species of microbes from such families.
- the components of all the glass-ceramic compositions suitable for ion-exchange, or glasses that are suitable for ion-exchange before being cerammed into a glass-ceramic, are given in terms of weight percent (wt%) as the oxide unless indicated otherwise.
- glass-ceramic is defined herein as a material that has both an amorphous component and a crystalline component. Glass-ceramics are
- microcrystalline solids produced by the controlled devitrification of glass.
- glasses are batched, melted, fabricated to shape, and then converted by a heat treatment to a partially- crystalline material with a highly uniform
- microstructure The basis of controlled crystallization lies in efficient internal nucleation, which allows development of fine, randomly oriented grains minimizing voids, micro-cracks, or other porosity. Because of the nature of the crystalline microstructure, the mechanical properties, including strength, elasticity, fracture toughness, and abrasion resistance, may be higher in GCs than in glass.
- An aspect of the disclosure is an antimicrobial article comprising a substrate comprising a glass-ceramic having a crystalline component, an amorphous component, and at least one antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper.
- Another aspect of the disclosure is a method of making a antimicrobial article having at least one selected antimicrobial agent therein, the method comprising the steps of providing a glass-ceramic substrate without an antimicrobial agent thereon, the glass-ceramic substrate having a crystalline component and an amorphous component; and subjecting said glass-ceramic substrate to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt to thereby form a antimicrobial glass-ceramic article, wherein the antimicrobial agent(s) is selected from the group consisting of copper, silver and a mixture of copper and silver.
- the antimicrobial GC article has a crystalline component in the range of 20-98 Vol% and an amorphous component in the range of 2-80 Vol%.
- the crystalline component can comprise a single crystalline phase of or a plurality of crystalline phases; that is, one or a plurality of crystalline phases.
- the antimicrobial GC article has a crystalline component in the range of 20-90 Vol% and an amorphous component in the range of 80-10 Vol%.
- the antimicrobial GC article has a crystalline component in the range of 40-90 Vol% and an amorphous component in the range of 60-10 Vol%.
- the crystalline component in some embodiments, is dispersed substantially uniformly within the glass component and exhibits a particle size ranging between 10 nm-20 microns, for example, 10 nm-19 microns, for example, 10 nm-18 microns, for example, 10 nm-17 microns, for example, 10 nm-16 microns, for example, 10 nm-15 microns, for example, 10 nm-14 microns, for example, 10 nm-13 microns, for example, 10 nm-12 microns, for example, 10 nm-1 1 microns, for example, 10 nm-10 microns, for example, 10 nm-9 microns, for example, 10 nm-8 microns, for example, 10 nm-7 microns, for example, 10 nm-6 microns, for example, 10 nm-5 microns, for example, 10 nm-4 microns, for example, 10 nm-3 microns, for example, 10 n
- the crystalline component has a particle size in the range of 10 nm-1 micron that is dispersed substantially uniformly within the glass component. In another embodiment the crystalline component has a particle size in the range of 10 nm-5 microns that is dispersed substantially uniformly within the glass component. In a further embodiment the crystalline component has a particle size in the range of 10 nm-2 microns that is dispersed substantially uniformly within the glass component.
- the crystalline component in some embodiments, is dispersed substantially uniformly within the glass component and exhibits an average particle size ranging between 10 nm-20 microns, for example, 10 nm-19 microns, for example, 10 nm-18 microns, for example, 10 nm-17 microns, for example, 10 nm-16 microns, for example, 10 nm-15 microns, for example, 10 nm-14 microns, for example, 10 nm-13 microns, for example, 10 nm-12 microns, for example, 10 nm-11 microns, for example, 10 nm-10 microns, for example, 10 nm-9 microns, for example, 10 nm-8 microns, for example, 10 nm-7 microns, for example, 10 nm-6 microns, for example, 10 nm-5 microns, for example, 10 nm-4 microns, for example, 10 nm-3 microns, for example, 10 nm
- the crystalline component has an average particle size in the range of 10 nm-1 micron that is dispersed substantially uniformly within the glass component. In another embodiment the crystalline component has an average particle size in the range of 10 nm-5 microns that is dispersed substantially uniformly within the glass component. In a further embodiment the crystalline component has an average particle size in the range of 10 nm-2 microns that is dispersed substantially uniformly within the glass component.
- a GC article without an antimicrobial agent therein or thereon is provided and subjected to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt.
- the antimicrobial agent salt and the alkali metal salt are present in the bath as a nitrate.
- the alkali metal can be, for example, sodium nitrate, potassium nitrate or a mixture thereof.
- concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath in some embodiments, is in the range of 1 wt% to 100 wt%.
- the balance of the bath can be a salt of an alkali metal or an alkaline earth metal.
- concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath is in the range of 5 wt% to 100 wt%.
- the concentration of the silver salt or copper salt, or mixture thereof, in the ion-exchange bath can be in the range of 0.01 wt% to 10 wt%. In one embodiment, the concentration of the silver salt or copper salt, or mixture thereof, in the ion-exchange bath is in the range of 0.01 wt% to 5 wt%.
- the ion-exchange temperatures can be in the range of 300-500°C with an ion-exchange time in the range of greater than 5 minutes to less than 6 hour. The temperature range could be higher if sulfate is present. The exact choice of time and temperature will be dependent on the depth of layer sought to be exchanged into the GC.
- the ion-exchange is carried out at a temperature in the range of 350-420°C, depending for example on the bath used, for a time of one hour or less time; for example without limitation, at a temperature of 420°C for a time in the range of 5 minutes to 20 minutes. If it is desired to have the antimicrobial ion-exchanged deeply into the GC, the ion-exchange can be carried out at higher temperatures for a longer time, for example without limitation, at a temperature of 450°C for a time in the range of 4-6 hours.
- the antimicrobial agent in the antimicrobial article is silver and the article has a surface concentration of silver, determined as Ag 2 0, of 1- 20 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1- 20 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag 2 0 and CuO, of 1-20 wt% .
- the antimicrobial agent in the antimicrobial article is silver and the article has a surface concentration of silver, determined as Ag 2 0, of 6 wt% or less. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 6 wt% or less. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag 2 0 and CuO, of 6 wt% or less.
- the antimicrobial agent in the antimicrobial article is silver and the article has a surface concentration of silver, determined as Ag 2 0, of 1-6 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1- 6 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag 2 0 and CuO, of 1-6 wt%.
- GC-forming components such as sand, sodium and/or potassium oxide, aluminum oxide, borate magnesia and/or other components as need to form a specific GC material were dry mixed in an appropriate vessel and a solution of the antimicrobial agent salt(s) was added to the dry materials during mixing, for example, by spraying the solution of antimicrobials agent s into the vessel.
- the solution is an aqueous solution.
- the methods can further comprising reducing the resulting antimicrobial agent(s) in the antimicrobial containing GC by heating in a reducing atmosphere at a selected temperature for a selected time to reduce the antimicrobial agent(s) to the zero valent form.
- the reducing conditions use a hydrogen atmosphere, for example, a pure H 2 environment, at a pressure in the range of 1-10 atmospheres at a temperature in the range of from 300°C to 600°C, for example, 350°C to 500°C for a time in the range of from 1-6 hours, for example, 2-6 hours or, for example, 1-5 hours.
- Other reducing substance such as forming gas can also be used.
- Glass-ceramics found useful for preparing antimicrobial GCs contain 20-98 Vol.% crystalline component and 2-80 Vol.% glass component.
- the antimicrobial glass-ceramics can be optically transparent or non-transparent and they can be colored or non-colored (that is, clear), where clear means no visible coloration.
- a transparent glass-ceramic can be either clear or colored.
- White and black are considered colors herein.
- the GC materials that can be used in practicing the disclosure can be selected from the group consisting of beta-spodumene solid solution (including both Li and Cu types, and solid solutions of Li, Cu, Mg, and Na), beta-quartz solid solutions
- Exemplary GCs used herein include beta-spodumene and beta-quartz solid solutions and Macor (Corning Incorporated) which is a machinable, white, odorless, porcelain-like (in appearance) GC material that has the appearance of porcelain and is 55 Vol% fluorophlogopite mica and 45 Vol% borosilicate glass.
- the antimicrobial GC is optically transparent and has a color or is uncolored. In another embodiment, the antimicrobial GC is translucent or opaque and has a color.
- the GCs may have compositions as described by the ranges in Table 1. The compositions are listed in weight percent.
- Figure 1 is an electron microprobe (EMP) analysis of a spodumene-type glass-ceramic after ion-exchange using a 5wt% AgN0 3 /95wt% NaN0 3 bath at 420°C for 20 minutes.
- Line 10 shows the wt % of Ag 2 0 present in the GC as a function of depth in microns.
- Figure 2A is an EMP analysis after ion-exchange using a 5wt%
- FIG. 2B is an Ag map of the glass-ceramic of Figure 2A. The light areas 12 show increased Ag concentration.
- Figure 3 is a photograph of a spodumene GC (a) after ion-exchange at 420°C for 20 minutes using 5wt% Ag in a NaN0 3 bath (top, GC is white) and (b) after reduction at 420°C for 5 hours in H 2 at 1 atmosphere pressure (bottom, GC is grey).
- Figure 4A and 4B are SEM micrographs of the surface (Figure 4A) and edge ( Figure 4B) of a spodumene GC after ion-exchange using a 5wt% AgN0 3 /95wt% NaN0 3 bath at 420°C for 20 minutes.
- Figures 5A-5C are SEM micrographs of the spodumene GC of Figures 4A/4B after reduction at 450°C for 5 hours in 1 atmosphere H 2 .
- Figure 6 is the EMP analysis of a spodumene GC containing 1 mole% CuO as-made after heat treatment at 1100 °C.
- compositions are shown in Table 2, Compositions A and B are examples of MacorTM and nepheline compositions, respectively, and examples C, D, E, and F are examples of beta-quartz. Table 3, examples K, L, M, N, O, and P, shows examples of beta-spodumene.
- Example Q in Table 3 is an exemplary fluormica glass- ceramic.
- Example R in Table 3 is an exemplary canasite glass-ceramic.
- Example S in Table 3 is an exemplary spodumene glass-ceramic.
- Tables 2 and 3 give
- the GCs listed in Tables 1, 2, and 3 can be used as a base GC and the ion-exchanged to provide or increase the amount of copper, silver, or combinations thereof in the GC.
- the GCs listed in Tables 1, 2, and 3 can have concentrations of silver, copper, or combinations thereof in the range of from 0- 20 wt%, for example, 1-20 wt%, for example, 1-19 wt%, for example, 1-18 wt%, for example, 1-17 wt%, for example, 1-16 wt%, for example, 1-15 wt %, for example, 1- 14 wt%, for example, 1-13 wt%, for example, 1-12 wt%, for example, 1-1 1 wt%, for example, 1-10 wt%, for example, 1-9 wt%, for example, 1-8 wt%, for example, 1-7 wt%, for example, 1-6 wt%, for example, 1-5 wt%, or, for example, 2-20 wt%, for example, 3-20 wt%, for example, 4-20 wt%, for example, 5-20 wt%, for example, 6- 20 wt
- Antimicrobial agent containing GCs have been tested for their antimicrobial activity, for example, using methods described below, and some of the antimicrobial GCs have a Log Reduction of >2.
- the article has an antimicrobial Log Reduction of >0.2, for example, >0.5, for example, >1, for example, >1.5, for example, >2, for example, >2.5, for example, >3, for example, >3.5, for example, >4, for example, >4.5, for example, >5.
- the article has an antiviral Log Reduction of >4 and an antibacterial Log Reduction >5.
- the article is capable of inhibiting at least 2 microbial species to a Log Reduction >1 within 1 hour.
- the article has an antibacterial Log Reduction of greater than 4 after 6 hours.
- Antibacterial testing for example, antibacterial-wet tests were performed on several exemplary glass-ceramics. Each testing sample glass-ceramic was cut into a glass-ceramic slide of lx 1 inch and put into petridish. Three uncoated glass-ceramic slides were used as negative controls. Gram negative E. coli bacteria were suspended in a 1/500 luria broth (LB) medium at a concentration of lX10 6 cell/ml. 156 ⁇ 1 of E. coli cell suspension was placed onto each sample surface and held in close contact by using a sterilized laboratory PARAFILM, and incubated for 6 hours at 37 C at saturation humidity (>95% relative humidity). Each sample was done in triplicate.
- LB luria broth
- PARAFILM sterilized laboratory PARAFILM
- PBS Phosphate Buffered Saline
- Antibacterial testing for example, antibacterial-dry tests were performed on several exemplary glass-ceramics. Each testing sample glass-ceramic was cut into a glass-ceramic slide of lx 1 inch 2 and put into petridish in triplicate. Non copper doped (uncoated) glass-ceramic slides were used as negative controls. Gram positive Staphylococcus aureus bacterial was cultured for at least 3 consecutive days before and on the day of testing, the inocula was culture for at least 48hours. The bacterial culture was Vortexed, serum(5% final concentration) was added and Triton X- 100(fmal concentration 0.01%) was added to the inocula.
- This exemplary GC was optically translucent to transparent. The treatment in H 2 and antimicrobial activity is listed in Table 4.
- An exemplary spodumene GC with Cu, example E in Table 2 had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 1000 ° C/4h to produce spodumene phase.
- the treatment in H 2 and antimicrobial activity is listed in Table 5.
- the treatment in H 2 and antimicrobial activity is listed in Table 6.
- An exemplary spodumene ion-exchanged GC with Ag (Ag was added by 5% AgN0 3 in a bath concentration ion-exchange), example S is the base GC prior to ion- exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 1000 ° C/4h to produce spodumene phase.
- the measured wt% of Ag 2 0 was 16 wt%.
- the treatment in H 2 and antimicrobial activity is listed in Table 7.
- An exemplary spodumene ion-exchanged GC with Ag is the base GC prior to ion-exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 1000 ° C/4h to produce spodumene phase.
- Ag was added by AgN0 3 ion-exchange at 350 ° C/10min as shown in Table 8.
- the GC was also Na ion-exchanged at 390 ° C/3.5h to strengthen the GC.
- the treatment in H 2 and antimicrobial activity is listed in Table 8.
- An exemplary mica GC with Cu, example A in Table 2 had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 950 ° C/4h to produce mica phase.
- the treatment in H 2 and antimicrobial activity is listed in Table 9.
- An exemplary canasite GC with Cu is the base GC prior to ion- exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 850 ° C/4h to produce canasite phase.
- the first exemplary canasite in Table 10 was ion-exchanged with Ag at 450 ° C/20min with 5% AgN0 3 .
- the treatment in H 2 and antimicrobial activity is listed in Table 10.
- An exemplary Macor GC with Cu, example A in Table 2 had a crystal phase developed using the following thermal treatment: 720 ° C/2h+ 950 ° C/4h to produce MacorTM phase.
- the first exemplary MacorTM in Table 11 was ion- exchanged with Ag at 450 ° C/20min with 5% AgN0 3 .
- the treatment in H 2 and antimicrobial activity is listed in Table 1 1.
- the treatment in H 2 and antimicrobial activity is listed in Table 12.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Inorganic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Glass Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The application discloses the formation of antimicrobial glass ceramic articles having an amorphous phase and a crystalline phase and an antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper. The antimicrobial glass ceramic can have a Log Reduction of >2.
Description
ANTIMICROBIAL GLASS-CERAMICS
[0001] This application claims the benefit of priority under 35 U.S.C. § 120 of U.S. Application Serial No. 13/649499 filed on October 11, 2012 which claims the benefit of priority under 35 U.S.C. § 119 of U.S. Provisional Application Serial No.
61/546302 filed October 12, 2011 the content of which is relied upon and
incorporated herein by reference in its entirety.
Field
[0002] This disclosure is directed to antimicrobial glass-ceramics, and in particular antimicrobial glass-ceramics containing silver, copper or a combination of silver and copper.
Background
[0003] There is a need for antimicrobial structures which have improved strength.
Summary
[0004] In one aspect the present disclosure is directed to the formation of an antimicrobial glass-ceramic ("GC") having an amorphous phase and a crystalline phase and an antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper.
[0005] Another aspect of the disclosure is a method of making a antimicrobial article having at least one selected antimicrobial agent therein, the method comprising the steps of providing a glass-ceramic substrate without an antimicrobial agent thereon, the glass-ceramic substrate having a crystalline component and an amorphous component; and subjecting said glass-ceramic substrate to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt to thereby form a antimicrobial glass-ceramic article, wherein the antimicrobial agent(s) is selected from the group consisting of copper, silver and a mixture of copper and silver.
[0006] The silver and copper, or mixture thereof, can be zero valent existing in the GC as Ag° or Cu°, which is the metallic form; can be ionic and exist in the GC as Ag+1, Cu+1 or Cu+2; or can be in the GC as a mixture of the zero valent and ionic forms of one or both agents, for example, Ag° and Cu+1 and/or Cu+2, Ag+1 and Cu°, and other combination of the zero valent and ionic species. The antimicrobial agent
can be incorporated into the GC by either (1) ion-exchange of a preformed GC using an ion-exchange bath containing one or both of the foregoing antimicrobial agents, or (2) by including one or both of the foregoing antimicrobial agents into batched materials used to prepare a glass that is then cerammed to form a GC. In (1), the antimicrobial agent will be present in the GC in ionic form, as the oxide, since nitrates of the antimicrobial agent can be used for the ion-exchange and because the nitrate species on the GC are easily decomposed during the ion-exchange process. While chlorides can also be used, their use can give rise to problems, for example, degradation of the GC and subsequent loss of its desirable properties. In (2) the antimicrobial agent is also deemed present as the oxide due to the conditions of melting, forming, nucleating and ceramming the glass, all of which can be carried out in air. In either case the resulting antimicrobial agent containing GC can be used as-is or can be subjected to a reduction step.
Brief Description of the Drawings
[0007] Figure 1 is an electron microprobe (EMP) analysis of a spodumene-type glass-ceramic after ion-exchange using a 5wt% AgN03/95wt% NaN03 bath at 420°C for 20 minutes.
[0008] Figure 2A is an EMP analysis after ion-exchange using a 5wt%
AgN03/95wt% NaN03 bath at 450°C for 5 hours.
[0009] Figure 2B is an Ag map of the glass-ceramic of Figure 2A.
[0010] Figure 3 is a photograph of a spodumene GC (a) after ion-exchange at 420°C for 20 minutes using 5wt% Ag in a NaN03 bath (top, GC is white) and (b) after reduction at 420°C for 5 hours in H2 at 1 atmosphere pressure (bottom, GC is grey).
[0011] Figure 4A and 4B are SEM micrographs of the surface (Figure 4A) and edge
(Figure 4B) of a spodumene GC after ion-exchange using a 5wt% AgN03/95wt%
NaN03 bath at 420°C for 20 minutes.
[0012] Figures 5A-5C are SEM micrographs of the spodumene GC of Figures 4A/4B after reduction at 450°C for 5 hours in 1 atmosphere H2.
[0013] Figure 6 is the EMP analysis of a spodumene GC containing 1 mole% CuO as-made after heat treatment at 1100°C.
Detailed Description
[0014] As used herein the term "antimicrobial," means an agent(s) or material, or a surface containing the agent(s) or material that will kill or inhibit the growth of microbes from at least two of families consisting of bacteria, viruses and fungi. The term as used herein does not mean it will kill or inhibit the growth of all species microbes within such families, but that it will kill or inhibit the growth or one or more species of microbes from such families. The components of all the glass-ceramic compositions suitable for ion-exchange, or glasses that are suitable for ion-exchange before being cerammed into a glass-ceramic, are given in terms of weight percent (wt%) as the oxide unless indicated otherwise. Methods of analyzing the contents of antimicrobial agents present on the surface of or/or into the depth of the GC, for example, silver, are described in the commonly owned U.S. Patent Application No. 13/197,312 filed on August 3, 2011 in the name of Nicholas Francis Borrelli et al, and titled "Coated, Antimicrobial, Chemically Strengthened Glass and Method of Making." The teachings of U.S. Patent Application No. 13/197,312 are incorporated herein by reference.
[0015] The term "glass-ceramic" is defined herein as a material that has both an amorphous component and a crystalline component. Glass-ceramics are
microcrystalline solids produced by the controlled devitrification of glass. To make glass-ceramics, glasses are batched, melted, fabricated to shape, and then converted by a heat treatment to a partially- crystalline material with a highly uniform
microstructure. The basis of controlled crystallization lies in efficient internal nucleation, which allows development of fine, randomly oriented grains minimizing voids, micro-cracks, or other porosity. Because of the nature of the crystalline microstructure, the mechanical properties, including strength, elasticity, fracture toughness, and abrasion resistance, may be higher in GCs than in glass.
[0016] An aspect of the disclosure is an antimicrobial article comprising a substrate comprising a glass-ceramic having a crystalline component, an amorphous component, and at least one antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper.
[0017] Another aspect of the disclosure is a method of making a antimicrobial article having at least one selected antimicrobial agent therein, the method comprising the steps of providing a glass-ceramic substrate without an antimicrobial agent thereon, the glass-ceramic substrate having a crystalline component and an amorphous component; and subjecting said glass-ceramic substrate to an ion-exchange process
using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt to thereby form a antimicrobial glass-ceramic article, wherein the antimicrobial agent(s) is selected from the group consisting of copper, silver and a mixture of copper and silver.
[0018] In one embodiment the antimicrobial GC article has a crystalline component in the range of 20-98 Vol% and an amorphous component in the range of 2-80 Vol%. The crystalline component can comprise a single crystalline phase of or a plurality of crystalline phases; that is, one or a plurality of crystalline phases. In another embodiment the antimicrobial GC article has a crystalline component in the range of 20-90 Vol% and an amorphous component in the range of 80-10 Vol%. In an additional embodiment the antimicrobial GC article has a crystalline component in the range of 40-90 Vol% and an amorphous component in the range of 60-10 Vol%.
[0019] The crystalline component, in some embodiments, is dispersed substantially uniformly within the glass component and exhibits a particle size ranging between 10 nm-20 microns, for example, 10 nm-19 microns, for example, 10 nm-18 microns, for example, 10 nm-17 microns, for example, 10 nm-16 microns, for example, 10 nm-15 microns, for example, 10 nm-14 microns, for example, 10 nm-13 microns, for example, 10 nm-12 microns, for example, 10 nm-1 1 microns, for example, 10 nm-10 microns, for example, 10 nm-9 microns, for example, 10 nm-8 microns, for example, 10 nm-7 microns, for example, 10 nm-6 microns, for example, 10 nm-5 microns, for example, 10 nm-4 microns, for example, 10 nm-3 microns, for example, 10 nm-2 microns, for example, 10 nm-1 microns, for example, 10 nm-900 nm, for example, 10 nm-850 nm, for example, 10 nm-800 nm, for example, 10 nm-750 nm, for example, 10 nm-700 nm, for example, 10 nm-650 nm, for example, 10 nm-600 nm, for example, 10 nm-550 nm, for example, 10 nm-500 nm, for example, 10 nm-450 nm, for example, 10 nm-400 nm, for example, 10 nm-350 nm, for example, 10 nm-300 nm. In one embodiment the crystalline component has a particle size in the range of 10 nm-1 micron that is dispersed substantially uniformly within the glass component. In another embodiment the crystalline component has a particle size in the range of 10 nm-5 microns that is dispersed substantially uniformly within the glass component. In a further embodiment the crystalline component has a particle size in the range of 10 nm-2 microns that is dispersed substantially uniformly within the glass component.
[0020] The crystalline component, in some embodiments, is dispersed substantially uniformly within the glass component and exhibits an average particle size ranging
between 10 nm-20 microns, for example, 10 nm-19 microns, for example, 10 nm-18 microns, for example, 10 nm-17 microns, for example, 10 nm-16 microns, for example, 10 nm-15 microns, for example, 10 nm-14 microns, for example, 10 nm-13 microns, for example, 10 nm-12 microns, for example, 10 nm-11 microns, for example, 10 nm-10 microns, for example, 10 nm-9 microns, for example, 10 nm-8 microns, for example, 10 nm-7 microns, for example, 10 nm-6 microns, for example, 10 nm-5 microns, for example, 10 nm-4 microns, for example, 10 nm-3 microns, for example, 10 nm-2 microns, for example, 10 nm-1 microns, for example, 10 nm-900 nm, for example, 10 nm-850 nm, for example, 10 nm-800 nm, for example, 10 nm- 750 nm, for example, 10 nm-700 nm, for example, 10 nm-650 nm, for example, 10 nm-600 nm, for example, 10 nm-550 nm, for example, 10 nm-500 nm, for example, 10 nm-450 nm, for example, 10 nm-400 nm, for example, 10 nm-350 nm, for example, 10 nm-300 nm. In one embodiment the crystalline component has an average particle size in the range of 10 nm-1 micron that is dispersed substantially uniformly within the glass component. In another embodiment the crystalline component has an average particle size in the range of 10 nm-5 microns that is dispersed substantially uniformly within the glass component. In a further embodiment the crystalline component has an average particle size in the range of 10 nm-2 microns that is dispersed substantially uniformly within the glass component.
[0021] In one embodiment, a GC article without an antimicrobial agent therein or thereon is provided and subjected to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt. In one embodiment the antimicrobial agent salt and the alkali metal salt are present in the bath as a nitrate. The alkali metal can be, for example, sodium nitrate, potassium nitrate or a mixture thereof. The concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath, in some embodiments, is in the range of 1 wt% to 100 wt%. The balance of the bath can be a salt of an alkali metal or an alkaline earth metal. In some embodiments, the concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath is in the range of 5 wt% to 100 wt%.
[0022] The concentration of the silver salt or copper salt, or mixture thereof, in the ion-exchange bath can be in the range of 0.01 wt% to 10 wt%. In one embodiment, the concentration of the silver salt or copper salt, or mixture thereof, in the ion-exchange bath is in the range of 0.01 wt% to 5 wt%.
[0023] The ion-exchange temperatures can be in the range of 300-500°C with an ion-exchange time in the range of greater than 5 minutes to less than 6 hour. The temperature range could be higher if sulfate is present. The exact choice of time and temperature will be dependent on the depth of layer sought to be exchanged into the GC. For example, when it is desired to primarily have the antimicrobial agent(s) ion-exchanged onto the surface or near the surface of the GC, the ion-exchange is carried out at a temperature in the range of 350-420°C, depending for example on the bath used, for a time of one hour or less time; for example without limitation, at a temperature of 420°C for a time in the range of 5 minutes to 20 minutes. If it is desired to have the antimicrobial ion-exchanged deeply into the GC, the ion-exchange can be carried out at higher temperatures for a longer time, for example without limitation, at a temperature of 450°C for a time in the range of 4-6 hours.
[0024] In some embodiments, in the antimicrobial article the antimicrobial agent is silver and the article has a surface concentration of silver, determined as Ag20, of 1- 20 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1- 20 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag20 and CuO, of 1-20 wt% .
[0025] In some embodiments, in the antimicrobial article the antimicrobial agent is silver and the article has a surface concentration of silver, determined as Ag20, of 6 wt% or less. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 6 wt% or less. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag20 and CuO, of 6 wt% or less.
[0026] In some embodiments, in the antimicrobial article the antimicrobial agent is silver and the article has a surface concentration of silver, determined as Ag20, of 1-6 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1- 6 wt%. In some embodiments, in the antimicrobial article the antimicrobial agent is a mixture of copper and silver and the article has a surface concentration of copper and silver, determined as Ag20 and CuO, of 1-6 wt%.
[0027] In another embodiment GC-forming components such as sand, sodium and/or potassium oxide, aluminum oxide, borate magnesia and/or other components as need to form a specific GC material were dry mixed in an appropriate vessel and a solution of the antimicrobial agent salt(s) was added to the dry materials during mixing, for example, by spraying the solution of antimicrobials agent s into the vessel. In some embodiments, the solution is an aqueous solution. After all of the antimicrobial salt containing solution has been added to the dry mixture and thoroughly mixed, the resulting batch of materials was melted and formed into a glass. Subsequently the glass was heated to a nucleation temperature for a selected time, the nucleation time, and then heated to a ceramming temperature for a selected time, the ceramming time, to form a glass-ceramic.
[0028] In both the foregoing methods, the methods can further comprising reducing the resulting antimicrobial agent(s) in the antimicrobial containing GC by heating in a reducing atmosphere at a selected temperature for a selected time to reduce the antimicrobial agent(s) to the zero valent form. The reducing conditions use a hydrogen atmosphere, for example, a pure H2 environment, at a pressure in the range of 1-10 atmospheres at a temperature in the range of from 300°C to 600°C, for example, 350°C to 500°C for a time in the range of from 1-6 hours, for example, 2-6 hours or, for example, 1-5 hours. Other reducing substance such as forming gas can also be used.
[0029] Glass-ceramics found useful for preparing antimicrobial GCs contain 20-98 Vol.% crystalline component and 2-80 Vol.% glass component. The antimicrobial glass-ceramics can be optically transparent or non-transparent and they can be colored or non-colored (that is, clear), where clear means no visible coloration. Thus, a transparent glass-ceramic can be either clear or colored. White and black are considered colors herein.
[0030] The GC materials that can be used in practicing the disclosure can be selected from the group consisting of beta-spodumene solid solution (including both Li and Cu types, and solid solutions of Li, Cu, Mg, and Na), beta-quartz solid solutions
(including beta-eucryptite and virgilite), nepheline solid solutions, carnegieite solid solutions, pollucite, leucite (K[AlSi206), trisilicic fluormicas (including phlogopite and biotite), tetrasilicic fluormicas (including taeniolite and polylithionite), alkali- bearing cordierite and osumilite, GCs containing substantial alkali alumino silicate or alkali borosilicate glass, canasite, agrellite and fluoramphiboles. Exemplary GCs
used herein include beta-spodumene and beta-quartz solid solutions and Macor (Corning Incorporated) which is a machinable, white, odorless, porcelain-like (in appearance) GC material that has the appearance of porcelain and is 55 Vol% fluorophlogopite mica and 45 Vol% borosilicate glass. In one embodiment, the antimicrobial GC is optically transparent and has a color or is uncolored. In another embodiment, the antimicrobial GC is translucent or opaque and has a color.
[0031] According to some embodiments, the GCs may have compositions as described by the ranges in Table 1. The compositions are listed in weight percent.
Table 1.
[0032] Figure 1 is an electron microprobe (EMP) analysis of a spodumene-type glass-ceramic after ion-exchange using a 5wt% AgN03/95wt% NaN03 bath at 420°C for 20 minutes. Line 10 shows the wt % of Ag20 present in the GC as a function of depth in microns.
[0033] Figure 2A is an EMP analysis after ion-exchange using a 5wt%
AgN03/95wt% NaN03 bath at 450°C for 5 hours. Data points show the wt % of Ag20 present in the GC as a function of depth in microns.
[0034] Figure 2B is an Ag map of the glass-ceramic of Figure 2A. The light areas 12 show increased Ag concentration.
[0035] Figure 3 is a photograph of a spodumene GC (a) after ion-exchange at 420°C for 20 minutes using 5wt% Ag in a NaN03 bath (top, GC is white) and (b) after reduction at 420°C for 5 hours in H2 at 1 atmosphere pressure (bottom, GC is grey).
[0036] Figure 4A and 4B are SEM micrographs of the surface (Figure 4A) and edge (Figure 4B) of a spodumene GC after ion-exchange using a 5wt% AgN03/95wt% NaN03 bath at 420°C for 20 minutes.
[0037] Figures 5A-5C are SEM micrographs of the spodumene GC of Figures 4A/4B after reduction at 450°C for 5 hours in 1 atmosphere H2.
[0038] Figure 6 is the EMP analysis of a spodumene GC containing 1 mole% CuO as-made after heat treatment at 1100 °C.
[0039] Exemplary compositions are shown in Table 2, Compositions A and B are examples of Macor™ and nepheline compositions, respectively, and examples C, D, E, and F are examples of beta-quartz. Table 3, examples K, L, M, N, O, and P, shows examples of beta-spodumene. Example Q in Table 3 is an exemplary fluormica glass- ceramic. Example R in Table 3 is an exemplary canasite glass-ceramic. Example S in Table 3 is an exemplary spodumene glass-ceramic. Tables 2 and 3 give
representative compositions of several of the glass-ceramic materials that were evaluated and tested for antimicrobial activity. According to some embodiments, the GCs listed in Tables 1, 2, and 3 can be used as a base GC and the ion-exchanged to provide or increase the amount of copper, silver, or combinations thereof in the GC. According to some embodiments, the GCs listed in Tables 1, 2, and 3 can have concentrations of silver, copper, or combinations thereof in the range of from 0- 20 wt%, for example, 1-20 wt%, for example, 1-19 wt%, for example, 1-18 wt%, for example, 1-17 wt%, for example, 1-16 wt%, for example, 1-15 wt %, for example, 1- 14 wt%, for example, 1-13 wt%, for example, 1-12 wt%, for example, 1-1 1 wt%, for example, 1-10 wt%, for example, 1-9 wt%, for example, 1-8 wt%, for example, 1-7 wt%, for example, 1-6 wt%, for example, 1-5 wt%, or, for example, 2-20 wt%, for example, 3-20 wt%, for example, 4-20 wt%, for example, 5-20 wt%, for example, 6- 20 wt%, for example, 7-20 wt%, for example, 8-20 wt%, for example, 9-20 wt%, for example, 10-20 wt%, for example, 11-20 wt%, for example, 12-20 wt%, for example, 13-20 wt%, for example, 14-20 wt%, for example, 15-20 wt%, for example.
Table 2.
Table 3.
[0040] Antimicrobial agent containing GCs have been tested for their antimicrobial activity, for example, using methods described below, and some of the antimicrobial GCs have a Log Reduction of >2. In some embodiments, the article has an antimicrobial Log Reduction of >0.2, for example, >0.5, for example, >1, for example, >1.5, for example, >2, for example, >2.5, for example, >3, for example, >3.5, for example, >4, for example, >4.5, for example, >5. In some embodiments, the article has an antiviral Log Reduction of >4 and an antibacterial Log Reduction >5. In some embodiments, the article is capable of inhibiting at least 2 microbial species to a Log Reduction >1 within 1 hour. In some embodiments, the article has an antibacterial Log Reduction of greater than 4 after 6 hours.
[0041] Antibacterial testing, for example, antibacterial-wet tests were performed on several exemplary glass-ceramics. Each testing sample glass-ceramic was cut into a glass-ceramic slide of lx 1 inch and put into petridish. Three uncoated glass-ceramic slides were used as negative controls. Gram negative E. coli bacteria were suspended in a 1/500 luria broth (LB) medium at a concentration of lX106cell/ml. 156μ1 of E.
coli cell suspension was placed onto each sample surface and held in close contact by using a sterilized laboratory PARAFILM, and incubated for 6 hours at 37 C at saturation humidity (>95% relative humidity). Each sample was done in triplicate. After 6 hours of incubation, 2ml of Phosphate Buffered Saline (PBS) buffer was added into each petridish. After shaking, both the slide and PARAFILM were washed, and all the solution from each petridish was collected and placed onto a LB agar plate. After a further 16hr incubation at 37 C incubator, bacteria colony formation was examined. Geometric means were used to calculate the log and percent reduction based on the colony number glass-ceramic and control glass- ceramic.
[0042] Antibacterial testing, for example, antibacterial-dry tests were performed on several exemplary glass-ceramics. Each testing sample glass-ceramic was cut into a glass-ceramic slide of lx 1 inch2 and put into petridish in triplicate. Non copper doped (uncoated) glass-ceramic slides were used as negative controls. Gram positive Staphylococcus aureus bacterial was cultured for at least 3 consecutive days before and on the day of testing, the inocula was culture for at least 48hours. The bacterial culture was Vortexed, serum(5% final concentration) was added and Triton X- 100(fmal concentration 0.01%) was added to the inocula. Each sample was inoculated with 20ul aliquot of the bacterial suspension, samples were allowed to dry for 30-40 minutes at room temperature, and at 42% relative humidity. The samples were exposed for two hours immediately after drying. After 2 hours, 4ml of PBS buffer was added into each petridish. After shaking, all the solution from each petridish was collected and placed onto Trypticase soy agar plates. After a further 24hr incubation at 37 C, bacteria colony formation was examined. Geometric means were used to calculate the log and percent reduction based on the colony number glass and control glass.
[0043] An exemplary beta-quartz GC with 5 wt% Cu, example E in Table 2, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 850°C/4h (this is a dual thermal treatment where the first step is a treatment at 720 C with a hold time of 2 hours and the second step is a treatment at 850 C for 4 hours. This nomenclature is used herein to describe dual thermal treatments) to produce beta- quartz phase. This exemplary GC was optically translucent to transparent. The treatment in H2 and antimicrobial activity is listed in Table 4.
Table 4.
[0044] An exemplary spodumene GC with Cu, example E in Table 2, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 1000°C/4h to produce spodumene phase. The treatment in H2 and antimicrobial activity is listed in Table 5.
Table 5.
[0045] An exemplary spodumene GC with 5 wt percent Ag, example N in Table 3, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 1000°C/4h to produce spodumene phase. The treatment in H2 and antimicrobial activity is listed in Table 6.
Table 6.
[0046] An exemplary spodumene ion-exchanged GC with Ag (Ag was added by 5% AgN03 in a bath concentration ion-exchange), example S is the base GC prior to ion- exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 1000°C/4h to produce spodumene phase. The measured wt% of Ag20 was 16 wt%. The treatment in H2 and antimicrobial activity is listed in Table 7.
Table 7.
[0047] An exemplary spodumene ion-exchanged GC with Ag, example S is the base GC prior to ion-exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 1000°C/4h to produce spodumene phase. Ag was added by AgN03 ion-exchange at 350°C/10min as shown in Table 8. The GC
was also Na ion-exchanged at 390°C/3.5h to strengthen the GC. The treatment in H2 and antimicrobial activity is listed in Table 8.
Table 8.
[0048] An exemplary mica GC with Cu, example A in Table 2, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 950°C/4h to produce mica phase. The treatment in H2 and antimicrobial activity is listed in Table 9.
Table 9.
[0049] An exemplary canasite GC with Cu, example R is the base GC prior to ion- exchange in Table 3, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 850°C/4h to produce canasite phase. The first exemplary canasite in Table 10 was ion-exchanged with Ag at 450°C/20min with 5% AgN03. The treatment in H2 and antimicrobial activity is listed in Table 10.
[0050] An exemplary Macor GC with Cu, example A in Table 2, had a crystal phase developed using the following thermal treatment: 720°C/2h+ 950°C/4h to produce Macor™ phase. The first exemplary Macor™ in Table 11 was ion- exchanged with Ag at 450°C/20min with 5% AgN03. The treatment in H2 and antimicrobial activity is listed in Table 1 1.
[0051] An exemplary nepheline GC with 5 wt% Cu, example B in Table 2, had a crystal phase developed using the following thermal treatment: 850°C/4h+ 1100°C/6h to produce nepheline phase. The treatment in H2 and antimicrobial activity is listed in Table 12.
Table 12.
[0052] The data indicates that at a Cu doping level of 1 wt % Cu the cerammed GC without H2 reduction had an antibacterial LR >2 (>99% bacteria reduction) and with H2 reduction had an LR >5 (>99.999 bacterial reduction). A beta-quartz containing GC prepared using Cu added to the batch materials before melting, forming and ceramming was found to have an as-made, no H2 reduction, antimicrobial activity of > 2, the Cu-GC being both antibacterial and antiviral. In one embodiment wherein the batch materials were doped to contain 5 wt % Cu prior to melting, forming and ceramming, the as-made, no H2 reduction antimicrobial activity as >5.
[0053] While some embodiments have been set forth for the purpose of illustration, the foregoing description should not be deemed to be a limitation on the scope of the disclosure or the appended claims. Accordingly, various modifications, adaptations, and alternatives may occur to one skilled in the art without departing from the spirit and scope of this disclosure or the appended claims.
Claims
1. An antimicrobial article comprising:
a substrate comprising a glass-ceramic having a crystalline component; an amorphous component; and at lease one antimicrobial agent selected from the group consisting of silver, copper, and a mixture of silver and copper.
2. The antimicrobial article according to claim 1, wherein the article has an antimicrobial Log Reduction of >0.2.
3. The antimicrobial article according to claim 1, wherein the article has an antiviral Log Reduction of >4 and an antibacterial Log Reduction >5.
4. The antimicrobial article according to claim 1, wherein the article is capable of inhibiting at least 2 microbial species to a Log Reduction >1 within 1 hour.
5. The antimicrobial article according to claim 1, wherein the article has an antibacterial Log Reduction of greater than 4 after 6 hours.
6. The antimicrobial article according to claim 1, wherein the antimicrobial agent is silver and the article has a surface concentration of silver, determined as Ag20, of 1-20 wt% .
7. The antimicrobial article according to claim 1, wherein the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1-20 wt% .
8. The antimicrobial article according to claim 1, wherein the glass-ceramic is selected from the group consisting of beta-spodumene solid solution, beta-quartz solid solutions, nepheline solid solutions, carnegieite solid solutions, pollucite, leucite (K[AlSi206), trisilicic fluormicas, tetrasilicic fluormicas, alkali-bearing cordierite and osumilite, glass-ceramics containing substantial alkali aluminosilicate or alkali borosilicate glass, canasite, agrellite and fluoramphiboles.
9. The antimicrobial article according to claim 1, wherein the glass-ceramic has crystalline component in the range of 20-98 Vol% and an amorphous component in the range of 2-80 Vol%, and wherein the crystalline component comprises one or a plurality of crystalline phases.
10. The antimicrobial article according to claim 1, wherein the glass-ceramic has crystalline component in the range of 20-90 Vol% and an amorphous component in the range of 10-80 Vol%, and wherein the crystalline component comprises one or a plurality of crystalline phases.
11. The antimicrobial article according to claim 1, wherein the glass-ceramic has crystalline component in the range of 40-90 Vol% and an amorphous component in the range of 10-60 Vol%, and wherein the crystalline component comprises one or a plurality of crystalline phases.
12. The antimicrobial article according to claim 1, wherein the crystalline component has a particle size in the range of 10 nm-20 microns, and the particles are dispersed substantially uniformly within the amorphous glass component.
13. The antimicrobial article according to claim 1, wherein the crystalline component has a particle size in the range of 10 nm-1 micron, and the particles are dispersed substantially uniformly within the glass component.
14. The antimicrobial article according to claim 1, wherein the crystalline component has a particle size in the range of 10 nm-500 nm, and the particles are dispersed substantially uniformly within the glass component.
15. The antimicrobial article according to claim 1, wherein the crystalline component has a particle size in the range of 100 nm-750 nm, and the particles are dispersed substantially uniformly within the glass component.
16. A method of making a antimicrobial article having at least one selected antimicrobial agent therein, the method comprising the steps of: providing a glass-ceramic substrate without an antimicrobial agent thereon, the glass-ceramic substrate having a crystalline component and an amorphous
component; and
subjecting said glass-ceramic substrate to an ion-exchange process using an ion-exchange bath containing at least one ion-exchangeable antimicrobial agent salt and an exchangeable alkali metal salt to thereby form a antimicrobial glass-ceramic article,
wherein the antimicrobial agent(s) is selected from the group consisting of copper, silver and a mixture of copper and silver.
17. The method according to claim 16, wherein the concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath is in the range of 1 wt% to 100 wt%.
18. The method according to claim 17, wherein the concentration of the salts containing the antimicrobial agent(s) in the ion-exchange bath is in the range of 5 wt% to 100 wt%.
19. The method according to claim 16, wherein the glass-ceramic substrate comprises a glass-ceramic selected from the group consisting of beta-spodumene solid solution, beta-quartz solid solutions, nepheline solid solutions, carnegieite solid solutions, pollucite, leucite (K[AlSi206), trisilicic fluormicas, tetrasilicic fluormicas, alkali-bearing cordierite and osumilite, glass-ceramics containing substantial alkali aluminosilicate or alkali borosilicate glass, canasite, agrellite and f uoramphiboles.
20. The method according to claim 16, wherein the glass-ceramic substrate has a crystalline component in the range of 20-98 Vol% and an amorphous component in the range of 2-80 Vol%, and wherein the crystalline component comprises one or a plurality of crystalline phases.
21. The method according to claim 16, wherein the glass-ceramic substrate has a crystalline component with a particle size in the range of 10 nm-20 microns, and wherein the particles are dispersed substantially uniformly within the amorphous component.
22. The method according to claim 16, wherein the antimicrobial agent is silver and the article has a surface concentration of silver, determined as Ag20, of 1-20 wt% .
23. The method according to claim 16, wherein the antimicrobial agent is copper and the article has a surface concentration of copper, determined as CuO, of 1 -20 wt%
24. The method according to claim 16, wherein the method further comprises reducing the antimicrobial agent in a hydrogen atmosphere at a pressure in the range of 1-10 atmospheres at a temperature in the range of 350°C to 500°C for a time in the range of 1-5 hours.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014535899A JP2014534201A (en) | 2011-10-12 | 2012-10-12 | Antibacterial glass ceramic |
CN201280060196.2A CN104080332A (en) | 2011-10-12 | 2012-10-12 | Antimicrobial glass-ceramics |
EP12778187.0A EP2765856A1 (en) | 2011-10-12 | 2012-10-12 | Antimicrobial glass-ceramics |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546302P | 2011-10-12 | 2011-10-12 | |
US61/546,302 | 2011-10-12 | ||
US13/649,499 US20140105953A1 (en) | 2012-10-11 | 2012-10-11 | Antimicrobial glass-ceramics |
US13/649,499 | 2012-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013055994A1 true WO2013055994A1 (en) | 2013-04-18 |
Family
ID=47074904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/059872 WO2013055994A1 (en) | 2011-10-12 | 2012-10-12 | Antimicrobial glass-ceramics |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2765856A1 (en) |
JP (1) | JP2014534201A (en) |
CN (1) | CN104080332A (en) |
TW (1) | TW201321031A (en) |
WO (1) | WO2013055994A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103484798A (en) * | 2013-09-29 | 2014-01-01 | 中国科学院金属研究所 | Application of amorphous alloy serving as antibacterial function material |
WO2016033425A1 (en) * | 2014-08-29 | 2016-03-03 | Corning Incorporated | Antimicrobial materials including exchanged and infused antimicrobial agents |
US9840438B2 (en) | 2014-04-25 | 2017-12-12 | Corning Incorporated | Antimicrobial article with functional coating and methods for making the antimicrobial article |
US10131574B2 (en) | 2013-06-17 | 2018-11-20 | Corning Incorporated | Antimicrobial glass articles and methods of making and using same |
EP3448822A4 (en) * | 2016-04-29 | 2019-12-18 | Kornerstone Materials Technology Co., Ltd | Antimicrobial chemically strengthened glass and optimization method for the manufacture thereof |
US11274057B2 (en) | 2013-11-19 | 2022-03-15 | Corning Incorporated | Ion exchangeable high damage resistance glasses |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170369369A1 (en) * | 2015-02-12 | 2017-12-28 | Kornerstone Materials Technology Company, Ltd. | Antimicrobial chemically strengthened glass and method for the manufacture thereof |
CN105731795B (en) * | 2016-05-11 | 2018-11-20 | 陈子睿 | A kind of high strength glass formula and preparation process |
WO2018026775A1 (en) * | 2016-08-02 | 2018-02-08 | Corning Incorporated | Methods for melting reactive glasses and glass-ceramics and melting apparatus for the same |
CN110809405A (en) * | 2017-07-10 | 2020-02-18 | 富士胶片株式会社 | Composition, film-attached substrate, method for producing film-attached substrate, and modified substrate |
CN113321428B (en) * | 2021-05-26 | 2023-05-09 | 胡波 | Antibacterial glass product and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004076371A2 (en) * | 2003-02-25 | 2004-09-10 | Schott Ag | Antimicrobial phosphate glass |
US20050069592A1 (en) * | 2001-08-22 | 2005-03-31 | Fechner Jorg Hinrich | Water-insoluble, antimicrobial silicate glass and use thereof |
US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
DE102005039298A1 (en) * | 2005-08-19 | 2007-02-22 | Schott Ag | Mixture or paste for providing glass or vitreous ceramic with antimicrobial finish, e.g. for ceramic hob and domestic, medical, food and other industrial applications, contains sulfate, antimicrobial metal as oxide and organic matrix |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002363868A1 (en) * | 2001-12-12 | 2003-06-23 | Schott Glas | Antimicrobial alkali-silicate glass ceramic and the use thereof |
DE10308186B4 (en) * | 2003-02-25 | 2007-01-04 | Schott Ag | Antimicrobial phosphate glass and its uses |
-
2012
- 2012-10-12 TW TW101137774A patent/TW201321031A/en unknown
- 2012-10-12 WO PCT/US2012/059872 patent/WO2013055994A1/en active Application Filing
- 2012-10-12 EP EP12778187.0A patent/EP2765856A1/en not_active Withdrawn
- 2012-10-12 JP JP2014535899A patent/JP2014534201A/en active Pending
- 2012-10-12 CN CN201280060196.2A patent/CN104080332A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050069592A1 (en) * | 2001-08-22 | 2005-03-31 | Fechner Jorg Hinrich | Water-insoluble, antimicrobial silicate glass and use thereof |
US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
WO2004076371A2 (en) * | 2003-02-25 | 2004-09-10 | Schott Ag | Antimicrobial phosphate glass |
DE102005039298A1 (en) * | 2005-08-19 | 2007-02-22 | Schott Ag | Mixture or paste for providing glass or vitreous ceramic with antimicrobial finish, e.g. for ceramic hob and domestic, medical, food and other industrial applications, contains sulfate, antimicrobial metal as oxide and organic matrix |
Non-Patent Citations (5)
Title |
---|
C MOHR ET AL: "Formation of silver particles and periodic precipitate layers in silicate glass induced by thermally assisted hydrogen permeation", J. PHYS.: CONDENS. MATTER, 1 January 2001 (2001-01-01), pages 525 - 536, XP055047412, Retrieved from the Internet <URL:http://www.mpi-halle.de/mpi/publi/pdf/691_01.pdf> [retrieved on 20121211] * |
FRANCISCO C. SERBENA ET AL: "Internal Residual Stresses in Sintered and Commercial Low Expansion Li2O-Al2O3-SiO2 Glass-Ceramics", JOURNAL OF THE AMERICAN CERAMIC SOCIETY, vol. 94, no. 4, 1 April 2011 (2011-04-01), pages 1206 - 1214, XP055047348, ISSN: 0002-7820, DOI: 10.1111/j.1551-2916.2010.04220.x * |
See also references of EP2765856A1 * |
STRNAD ET AL: "Role of the glass phase in bioactive glass-ceramics", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 13, no. 5, 1 January 1992 (1992-01-01), pages 317 - 321, XP024142188, ISSN: 0142-9612, [retrieved on 19920101], DOI: 10.1016/0142-9612(92)90056-T * |
TOSHIHIRO KASUGA ET AL: "Porous Glass-Ceramics with Bacteriostatic Properties in Silver-Containing Titanium Phosphates: Control of Release of Silver Ions from Glass-Ceramics into Aqueous Solution", JOURNAL OF THE AMERICAN CERAMIC SOCIETY, vol. 80, no. 3, 1 March 1997 (1997-03-01), pages 777 - 780, XP055047045, ISSN: 0002-7820, DOI: 10.1111/j.1151-2916.1997.tb02898.x * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10131574B2 (en) | 2013-06-17 | 2018-11-20 | Corning Incorporated | Antimicrobial glass articles and methods of making and using same |
CN103484798A (en) * | 2013-09-29 | 2014-01-01 | 中国科学院金属研究所 | Application of amorphous alloy serving as antibacterial function material |
CN103484798B (en) * | 2013-09-29 | 2016-03-23 | 中国科学院金属研究所 | Amorphous alloy is as the application of antibiotic functional material |
US11274057B2 (en) | 2013-11-19 | 2022-03-15 | Corning Incorporated | Ion exchangeable high damage resistance glasses |
US9840438B2 (en) | 2014-04-25 | 2017-12-12 | Corning Incorporated | Antimicrobial article with functional coating and methods for making the antimicrobial article |
WO2016033425A1 (en) * | 2014-08-29 | 2016-03-03 | Corning Incorporated | Antimicrobial materials including exchanged and infused antimicrobial agents |
CN107105648A (en) * | 2014-08-29 | 2017-08-29 | 康宁股份有限公司 | Include the antimicrobial material of the antimicrobial reagent through exchanging and through impregnating |
EP3448822A4 (en) * | 2016-04-29 | 2019-12-18 | Kornerstone Materials Technology Co., Ltd | Antimicrobial chemically strengthened glass and optimization method for the manufacture thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2765856A1 (en) | 2014-08-20 |
JP2014534201A (en) | 2014-12-18 |
TW201321031A (en) | 2013-06-01 |
CN104080332A (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2765856A1 (en) | Antimicrobial glass-ceramics | |
US20140370066A1 (en) | Antimicrobial Glass-Ceramics | |
JP6896764B2 (en) | Chemically fortified antibacterial glass and optimization methods for its production | |
US20060142413A1 (en) | Antimicrobial active borosilicate glass | |
AU2012238401B2 (en) | Composition comprising antimicrobial metal ions and a quaternary cationic surfactant | |
US20140079807A1 (en) | Antimicrobial action of copper in glass | |
US20120034435A1 (en) | Coated, antimicrobial, chemically strengthened glass and method of making | |
US20080085326A1 (en) | Antimicrobial material compositions enriched with different active oxygen species | |
JP6576457B2 (en) | Chemically strengthened antimicrobial glass and method for producing the same | |
US20140356406A1 (en) | Antimicrobial Articles and Methods of Making and Using Same | |
TW201422421A (en) | Glass frit antimicrobial coating | |
Sánchez et al. | Bioactivity assessment of ZSM-5 type zeolite functionalized with silver or zinc | |
CN100403907C (en) | Inorganic bactericidal agent and its use | |
US10981825B2 (en) | Antimicrobial articles with silver-containing alkali silicate coating and methods of making thereof | |
Baghbani et al. | Production and characterization of a Ag-and Zn-doped glass-ceramic material and in vitro evaluation of its biological effects | |
JPH0541759B2 (en) | ||
Yuan et al. | Functionally modified zeolite powders for delivering antibacterial performance to cellulosic paper | |
CN112938925B (en) | Novel antibacterial silver compound titanium oxide silver phosphate and preparation method thereof | |
CN113826616B (en) | Preparation method of composite antibacterial material and application of composite antibacterial material in special paper | |
CN118104645B (en) | Preparation method of hectorite with antibacterial property | |
JP4336937B2 (en) | Antibacterial agent and method for producing the same | |
Ciołek et al. | In Vitro Studies of Antibacterial Activity of Bioglasses Releasing Ag+ | |
CN115645547A (en) | Silver-containing antibacterial agent and preparation method and application thereof | |
CN114380497A (en) | Borosilicate antimicrobial tempered glass and manufacturing method thereof | |
Bingshe et al. | Study on the heat resistant property of Ag/4A antibacterial agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12778187 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014535899 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012778187 Country of ref document: EP |